Human T helper type 1 dichotomy: origin, phenotype and biological activities

Immunology

Volumn 144, Issue 3, 2015, Pages 343-351

  Annunziato, Francesco ^a,b   Cosmi, Lorenzo ^a,b   Liotta, Francesco ^a,b   Maggi, Enrico ^a,b   Romagnani, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

cell differentiation; T cells; T helper type 1 type 2 type17 cells

Indexed keywords

EID: 85009701498     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/IMM.12399     Document Type: Article

References (82)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 175:5–14.
2. Del Prete G, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88:346–59.
3. Parronchi P, Macchia D, Piccinni MP et al. Allergen-and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 1991; 146:3413–8.
4. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12:256–7.
5. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchrooo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441:235–8.
6. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8:639–46.
7. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849–61.
8. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in face of changing circumstances. Nat Immunol 2010; 11:674–80.
9. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol 2012; 33:505–12.
10. Maggi L, Santarlasci V, Capone M et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol 2012; 42:3180–8.
11. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S. Natural killer cell stimulatory factor (interleukin 12, IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199–204.
12. + T cells through IL-12 production by Listeria-induced macrophages. Science 1993; 260:547–9.
13. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1:135–45.
14. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19:423–74.
15. Parronchi P, De Carli M, Manetti R et al. IL-4 and IFN (a and c) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149:2977–83.
16. Romagnani S. Induction of TH1 and TH2 responses: a key role for the ‘natural’ immune response? Immunol Today 1992; 13:379–81.
17. Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003; 24:207–12.
18. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998; 63:418–28.
19. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 2004; 117:515–26.
20. Liotta F, Frosali F, Querci V et al. Human immature myeloid dendritic cells trigger a TH2-polarizing program via Jagged-1/Notch interaction. J Allergy Clin Immunol 2008; 121:1000–5.
21. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of TH1/TH2 polarization. Immunol Today 2000; 21:479–83.
22. Bonecchi R, Bianchi G, Bordignon PP et al. Differentiual expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129–34.
23. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391:344–5.
24. Klose CS, Flach M, Mohle L et al. Differentiation of type 1 ILCs from a common pro-genitor to all helper-like innate lymphoid cell lineages. Cell 2014; 157:340–56.
25. Mariotti S, Del Prete GF, Mastromauro C, De Carli M, Romagnani S, Ricci M, Pincher-a A. The autoimmune infiltrate of Basedow’s disease: analysis of clonal level and comparison with Hashimoto’s thyroiditis. Exp Clin Endocrinol 1991; 97:139–46.
26. Windhagen A, Nicholson LB, Weiner HL, Kuchroo VK, Hafler DA. Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol 1996; 63:171–86.
27. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34–8.
28. Quayle AJ, Chomarat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cyto-kine patterns. Scand J Immunol 1993; 38:75–82.
29. Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper predominante and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997; 150:823–32.
30. Moller DR, Forman JD, Liu MC et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156:4952–60.
31. D’Elios MM, Josien R, Manghetti M et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int 1997; 51:1876–84.
32. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33–43.
33. Benagiano M, D’Elios MM, Amedei A et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol 2005; 174:6509–17.
34. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227–57.
35. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18:263–6.
36. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951–7.
37. Cua DJ, Cua J, Sherlock Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421:744–8.
38. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchrooo VK. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 2004; 200:79–87.
39. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715–25.
40. Veldhoen M, Stockinger B. TGFb1, a ‘Jack of all trades’, the link with pro-inflammatory IL-17-producing T cells. Trend Immunol 2006; 27:358–61.
41. Li M, Wan YY, Flavell RA. T cell-produced transforming growth factor-b1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity 2007; 26:579– 91.
42. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORct directs the differentiation program of proinflammatory IL-17 T helper cells. Cell 2006; 126:1121–31.
43. Yang XO, Pappu BP, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR a and ROR c. Immunity 2008; 28:29–39.
44. Durant L1, Watford WT, Ramos HL et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010; 32:605–15.
45. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulatory factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519–27.
46. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454–67.
47. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119–27.
48. Tato CM, Laurence A, O’Shea JJ. Helper T cell differentiation enters a new era: le roi est mort; vive le roi ! J Exp Med 2006; 203:809–12.
49. Chen Z, Tato CM, Muul L, Laurence A, O’Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007; 56:2936–46.
50. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950–7.
51. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1b and 6 but not transforming growth factor-b are essential for the differentiation of interleukin-17-producing human T helper cells. Nat Immunol 2007; 8:942–9.
52. + T-cell precursor. J Exp Med 2008; 205:1903–16.
53. Ghoreschi K, Laurence A, Yang XP et al. Generation of pathogenic TH17 cells in the absence of TGF-b signaling. Nature 2010; 467:967–71.
54. Chung Y, Chang SH, Martinez GJ et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009; 30:576–87.
55. Santarlasci V, Maggi L, Capone M et al. Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity 2012; 36:201–14.
56. Chu CC, Paul WE. Expressed genes in interleukin-4 treated B cells identified by cDNA representational difference analysis. Mol Immunol 1998; 35:487–502.
57. Boulland ML, Marquet J, Molinier-Frenkel V et al. Human IL4I1 is a secreted L-phenyl-alanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood 2007; 110:220–7.
58. Santarlasci V, Maggi L, Mazzoni A et al. IL-4-induced gene 1 maintains high Tob1 expression that contributes to TCR unresponsiveness in human T helper 17 cells. Eur J Immunol 2014; 44:654–61.
59. + T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 2011; 63:2504–15.
60. Maggi L, Cimaz R, Capone M et al. Eternecept inhibits the tumor necrosis factor a-driven shift of Th17 lymphocytes toward nonclassic Th1 phenotype in juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:1372–7.
61. Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T, Radbruch A, Chang HD. IFN-c and IL-12 synergize to convert in vivo generated Th17 into Th1/ Th17 cells. Eur J Immunol 2010; 40:3017–27.
62. Duhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E. Cutting edge: the pathogenicity of IFN-c-producing Th17 cells is independent of T-bet. J Immunol 2013; 190:4478–82.
63. + Th1/17 cells that are specific for pathogenic and commensal microbes. J Immunol 2014; 193:120–9.
64. Romagnani S. The TH1/TH2 paradigm in disease. Molecular Biology Inteligence Unit. Austin, TX, USA: R.G. Landes Company, 1997.
65. Manetti R, Annunziato F, Tomasevic L, Giannòo V, Parronchi P, Romagnani S, Maggi E. Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-a and interleukin-12. Eur J Immunol 1995; 25:2656–60.
66. Clerici M. Shearer GM: a TH1 to TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:412–7.
67. Nistala K, Adams S, Cambrook H et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010; 107:14751–6.
68. Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009; 206:525–34.
69. + T lymphocytes infiltrate Crohn’s disease-associated perianal fistulas and are reduced by anti-TNF-a local therapy. Int Arch Allergy Immunol 2013; 161:81–6.
70. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. Preferential recruitment of interferon-c-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009; 66:390–402.
71. Lee Y, Awasthi A, Yosef N et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991–9.
72. Codarri L, Gyüulvòeszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. RORct drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12:560–7.
73. Piper C, Pesenacker AM, Bending D, Thirugnanabalan B, Varsani H, Wedderburn LR, Nistala K. T cell expression of granulocyte macrophage colony stimulating factor in juvenile arthritis is contingent upon Th17 plasticity. Arthritis Rheumatol 2014; 66:1955– 60.
74. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014; 211:89–104.
75. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to inter-leukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
76. Hueber W, Sands BE, Lewitzky S et al. Secukinumab in Crohn’s disease study group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Cro-hn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut 2012; 61:1693–700.
77. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in kerat-inocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129:2175–83.
78. Cai Y, Shen X, Ding C et al. Pivotal role of dermal IL-17-producing cd T cells in skin inflammation. Immunity 2011; 35:596–610.
79. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Leb-wohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580–92.
80. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135:1130–41.
81. Burmester GR, Weinblatt ME, McInnes IB et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1445–52.
82. Fauber BP, Magnuson S. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-c (RORc or RORc). J Med Chem 2014; 57:5871–92.